D-Artepp

D-Artepp (marketed by Greenlife Pharmaceuticals) is a fixed-dose Artemisinin-based Combination Therapy (ACT) antimalarial. It combines two active pharmaceutical ingredients: dihydroartemisinin (DHA) and piperaquine phosphate.

• Dihydroartemisinin (DHA): The primary active metabolite of artemisinin derivatives. It acts rapidly on blood-stage erythrocytic parasites (trophozoites) by generating intra-parasitic free radicals in the presence of heme iron. This leads to fast parasite clearance and rapid relief of fever and symptoms within hours.

• Piperaquine Phosphate: A long-acting lipophilic bisquinoline antimalarial derivative. It accumulates inside the parasite’s food vacuole and inhibits the conversion of toxic free heme into inert hemozoin. The accumulation of toxic heme causes parasitic cell destruction, providing extended therapeutic coverage to clear residual parasites and prevent relapse.

D-Artepp is available in soft gelatin capsule (softgel) and tablet formulations, which offer smooth oral administration and reliable gastrointestinal absorption.

Primary Medical Indications

D-Artepp is indicated for adults, adolescents, and children for the treatment of acute parasitic infections:

• Uncomplicated Plasmodium falciparum Malaria: First-line curative treatment for acute, uncomplicated malaria caused by P. falciparum or mixed species infections containing P. falciparum.

• Multi-Drug Resistant Malaria: Highly effective against P. falciparum strains showing resistance to older antimalarial monotherapies such as chloroquine, sulfadoxine-pyrimethamine (Fansidar), or quinine.

• Treatment of Non-falciparum Blood-Stage Parasites: Effective against erythrocytic schizonts of Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae (radical cure for liver hypnozoites in P. vivax and P. ovale requires adjunct therapy with primaquine or tafenoquine).

Key Product Specifications & Dosing Forms

Critical Safety Guidelines & Precautions

• Empty Stomach / Low-Fat Meal Dosing: Piperaquine absorption increases substantially when co-administered with high-fat meals, which can elevate systemic exposure and increase the risk of cardiac side effects. Take D-Artepp on an empty stomach (or with low-fat food).

• QTc Prolongation Warning: Piperaquine has the potential to prolong the QTc interval on an ECG. Avoid co-administration with other QT-prolonging drugs (e.g., macrolides, antiarrhythmics, quinine, halofantrine) or in patients with known congenital long QT syndrome or uncorrected electrolyte imbalances.

• Re-Dosing Protocol for Vomiting: If vomiting occurs within 30 to 60 minutes of taking a dose, re-administer a full replacement dose immediately. If persistent vomiting prevents oral retention, switch immediately to parenteral antimalarial therapy (e.g., IV or IM artesunate).

• Not for Severe/Complicated Malaria: Contraindicated for severe or complicated malaria (e.g., cerebral malaria, severe anemia, persistent vomiting). Severe cases require immediate intravenous antimalarial intervention.

• Prophylaxis Restriction: D-Artepp is strictly a therapeutic curative agent and must never be used for malaria prophylaxis.